In October 2015, RheumNow published 76 tweets about impactful news, research and teaching points that impact the rheumatology community. In October, RN had a reach (impressions) of 49,500, 79 mentions, and over 2000 visits to RheumNow.com to check out what we publish.
Off-label use of prescription drugs was associated with adverse drug events in a study of patients in Canada, according to an article published online by JAMA Internal Medicine.
Using Medicare claims data, a retrospective cohort study analyzed the risk of a second non-melanomatous skin cancer (NMSC) in 9460 individuals (6841 with RA and 2788 with IBD).
Each month, RheumNow reviews compiled listings of drug shortages germane to the practive of rheumatology using several sources. If you have suggestions or information about specific drug shortages or drug safety issues please email us at info@rheumnow.
A Danish cohort study examined patients with hyperuricemia and compared outcomes in those proven to have urate crystal deposition (317 patients) and matched 1:1 to patients without urate crystals.
MONTREAL -- An immunosuppressive drug was as effective as a standard agent for interstitial lung disease (ILD) associated with scleroderma, a researcher said.
A team of Japanese investigators examine 126 patients with ANCA-associated renal vasculitis to see if ANCA levels would predict disease relapse.
Using death certificate data from US National Vital Statistics System of the National Center for Health Statistics (NCHS) and the Centers for Disease Control and Prevention, JAMA reports a downward trend in death rates in the USA from 1969 - 2013).
The October 27 issue of JAMA reports a study of federal marketplace insurance plans shows roughly 15 percent completely lacked in-network physicians for at least one specialty, a practice found among multiple states and issuers.
Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.
Despite concerns over safety, the FDA Arthritis Advisory Committee voted favorably to approve lesinurad (LES) at a meeting held Friday, October 23, 2015. Overall, panel members felt the potential benefits of LES outweighed the safety concerns reviewed by the FDA presenters.
Vertebral fractures are not uncommon in patients with ankylosing spondylitis and spondyloarthritis.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
